The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity

Chemical Research in Toxicology

Volumn 22, Issue 1, 2009, Pages 208-217

  Mladěnka, Přemysl ^a   Kalinowski, Danuta S ^c   Hašková, Pavlína ^a   Bobrovová, Zuzana ^a   Hrdina, Radomír ^a   Simůnek, Tomáš ^a   Nachtigal, Petr ^a   Semecký, Vladimír ^a   Vávrová, Jaroslava ^b   Holečková, Magdaléna ^b   Palicka, Vladimir ^b   Mazurová, Yvona ^b   Jansson, Patric J ^c   Richardson, Des R ^c  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRIDYLCARBOXALDEHYDE 2 THIOPHENECARBOXYL HYDRAZONE; CATECHOLAMINE; CHELATING AGENT; DEFEROXAMINE; HYDRAZONE DERIVATIVE; IRON COMPLEX; ISOPRENALINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; HEART MUSCLE CELL; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; IRON BINDING CAPACITY; IRON CHELATION; LIPOPHILICITY; MALE; MORTALITY; NONHUMAN; OXIDATION REDUCTION REACTION; RAT;

ANIMALS; CATECHOLAMINES; CELL LINE; DEFEROXAMINE; IRON; IRON CHELATING AGENTS; ISOPROTERENOL; MALE; MYOCYTES, CARDIAC; OXIDATION-REDUCTION; RATS; RATS, WISTAR; THIOPHENES;

RATTUS;

EID: 61849164990     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx800331j     Document Type: Article

References (70)

1. Davis, B. A., and Porter, J. B. (2000) Long-term outcome of continuous 24-h deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 95, 1229-1236.
2. Hershko, C., Link, G., and Konijn, A. M. (2002) Cardioprotective effect of iron chelators. Adv. Exp. Med. Biol. 509, 77-89.
3. Hrdina, R., Gersl, V., Klimtova, I., Simunek, T., Machackova, J., and Adamcova, M. (2000) Anthracycline-induced cardiotoxicity. Acta. Med. (Hradec Kralove) 43, 75-82.
4. Kalinowski, D. S., and Richardson, D. R. (2007) Future of toxicology - Iron chelators and differing modes of action and toxicity: The changing face of iron chelation therapy. Chem. Res. Toxicol. 20, 715-720.
5. Olivieri, N. F., and Brittenham, G. M. (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89, 739-761.
6. Tam, T. F., Leung-Toung, R., Li, W., Wang, Y., Karimian, K., and Spino, M. (2003) Iron chelator research: Past, present, and future. Curr. Med. Chem. 10, 983-995.
7. Kalinowski, D. S., and Richardson, D. R. (2005) Evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 57, 1-37.
8. Jewett, S. L., Eggling, S., and Geller, L. (1997) Novel method to examine the formation of unstable 2:1 and 3:1 complexes of catecholamines and iron(III). J. Inorg. Biochem. 66, 165-173.
9. Mentasti, E., Pelizzetti, E., and Baiocchi, C. (1976) Interactions of iron(III) with adrenaline, L-Dopa and other catechol derivatives. Electron-exchange kinetics and mechanism in acidic perchlorate media. J. Inorg. Nucl. Chem. 38, 2017-2021.
10. Rajan, K. S., Davis, J. M., and Colburn, R. W. (1971) Metal chelates in the storage and transport of neurotransmitters: interactions of metal ions with biogenic amines. J. Neurochem. 18, 345-364.
11. Kaye, D. M., Lefkovits, J., Jennings, G. L., Bergin, P., Broughton, A., and Esler, M. D. (1995) Adverse consequences of high sympathetic nervous activity in the failing human heart. J. Am. Coll. Cardiol. 26, 1257-1263.
12. Kloner, R. A. (2006) Natural and unnatural triggers of myocardial infarction. Prog. Cardiovasc. Dis. 48, 285-300.
13. Chagoya de Sanchez, V., Hernandez-Munoz, R., Lopez-Barrera, F., Yanez, L., Vidrio, S., Suarez, J., Cota-Garza, M. D., Aranda-Fraustro, A., and Cruz, D. (1997) Sequential changes of energy metabolism and mitochondrial function in myocardial infarction induced by isoproterenol in rats: a long-term and integrative study. Can. J. Physiol. Pharmacol. 75, 1300-1311.
14. Rona, G. (1985) Catecholamine cardiotoxicity. J. Mol. Cell. Cardiol. 17, 291-306.
15. Dhalla, K. S., Rupp, H., Beamish, R. E., and Dhalla, N. S. (1996) Mechanisms of alterations in cardiac membrane Ca2+ transport due to excess catecholamines. Cardiovasc. Drugs Ther. 10 (Suppl. 1), 231-238.
16. Yates, J. C., and Dhalla, N. S. (1975) Induction of necrosis and failure in the isolated perfused rat heart with oxidized isoproterenol. J. Mol. Cell. Cardiol. 7, 807-816.
17. Persoon-Rothert, M., van der Valk-Kokshoorn, E. J., Egas-Kenniphaas, J. M., Mauve, I., and van der Laarse, A. (1989) Isoproterenol-induced cytotoxicity in neonatal rat heart cell cultures is mediated by free radical formation. J. Mol. Cell Cardiol. 21, 1285-1291.
18. Remiao, F., Carvalho, M., Carmo, H., Carvalho, F., and Bastos, M. L. (2002) Cu2+-induced isoproterenol oxidation into Isoprenochrome in adult rat calcium-tolerant cardiomyocytes. Chem. Res. Toxicol. 15, 861-869.
19. Nappi, A. J., and Vass, E. (1997) Comparative studies of enhanced iron-mediated production of hydroxyl radical by glutathione, cysteine, ascorbic acid, and selected catechols. Biochim. Biophys. Acta 1336, 295-302.
20. Rajadurai, M., and Stanely Mainzen Prince, P. (2006) Preventive effect of naringin on lipid peroxides and antioxidants in isoproterenol-induced cardiotoxicity in Wistar rats: biochemical and histopathological evidences. Toxicology 228, 259-268.
21. Rajadurai, M., and Stanely Mainzen Prince, P. (2007) Preventive effect of naringin on cardiac markers, electrocardiographic patterns and lysosomal hydrolases in normal and isoproterenol-induced myocardial infarction in Wistar rats. Toxicology 230, 178-188.
22. Ambrosio, G., Zweier, J. L., Jacobus, W. E., Weisfeldt, M. L., and Flaherty, J. T. (1987) Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury. Circulation 76, 906-915.
23. Bolli, R., Patel, B. S., Jeroudi, M. O., Li, X. Y., Triana, J. F., Lai, E. K., and McCay, P. B. (1990) Iron-mediated radical reactions upon reperfusion contribute to myocardial "stunning". Am. J. Physiol. 259, H1901-1911.
24. DeBoer, D. A., and Clark, R. E. (1992) Iron chelation in myocardial preservation after ischemia-reperfusion injury: The importance of pretreatment and toxicity. Ann. Thorac. Surg. 53, 412-418.
25. Reddy, B. R., Wynne, J., Kloner, R. A., and Przyklenk, K. (1991) Pretreatment with the iron chelator desferrioxamine fails to provide sustained protection against myocardial ischaemia-reperfusion injury. Cardiovasc. Res. 25, 711-718.
26. Hershko, C., Abrahamov, A., Konijn, A. M., Breuer, W., Cabantchik, I. Z., Pootrakul, P., and Link, G. (2003) Objectives and methods of iron chelation therapy. Bioinorg. Chem. Appl. 151-168.
27. Richardson, D. R., and Ponka, P. (1998) Pyridoxal isonicotinoyl hydrazone and its analogues: Potential orally effective iron-chelating agents for the treatment of iron overload disease. J. Lab. Clin. Med. 131, 306-315.
28. Richardson, D. R., Becker, E., and Bernhardt, P. V. (2000) Iron chelators and uses thereof. Australian Patent Application 73992/00; European Patent Application 00962062.6; Japanese Patent Application 2001-521321; Indian Patent Application IN/PCT/2002/00286; Canadian Patent Application 2,383,721; New Zealand Patent Application 517660; U.S. Patent Application 10/069923; Indonesian Patent Application W-00200200762; Chinese Patent Application 00812399.3; National Phase of PCT/AU00/01050.
29. Bernhardt, P. V., Chin, P., Sharpe, P. C., and Richardson, D. R. (2007) Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity. Dalton Trans. 3232-3244.
30. Becker, E., and Richardson, D. R. (1999) Development of novel aroylhydrazone ligands for iron chelation therapy: 2-Pyridylcarbox-aldehyde isonicotinoyl hydrazone analogs. J. Lab. Clin. Med. 134, 510-521.
31. Wong, C. S., Kwok, J. C., and Richardson, D. R. (2004) PCTH: A novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice. Biochim. Biophys. Acta 1739, 70-80.
32. Richardson, D. R., Mouralian, C., Ponka, P., and Becker, E. (2001) Development of potential iron chelators for the treatment of Friedreich's ataxia: Ligands that mobilize mitochondrial iron. Biochim. Biophys. Acta 1536, 133-140.
33. Chaston, T. B., and Richardson, D. R. (2003) Redox chemistry and DNA interactions of the 2-pyridyl-carboxaldehyde isonicotinoyl hydrazone class of iron chelators: Implications for toxicity in the treatment of iron overload disease. J. Biol. Inorg. Chem. 8, 427-438.
34. Lim, C. K., Kalinowski, D. S., and Richardson, D. R. (2008) Protection against hydrogen peroxide-mediated cytotoxicity by novel iron chelators in fibroblasts from control and Friedreich's ataxia patients. Mol. Pharmacol. 74, 225-235.
35. Yancy, S. L., Shelden, E. A., Gilmont, R. R., and Welsh, M. J. (2005) Sodium arsenite exposure alters cell migration, focal adhesion localization and decreases tyrosine phosphorylation of focal adhesion kinase in H9C2 myoblasts. Toxicol. Sci. 84, 278-86.
36. Simunek, T., Sterba, M., Popelova, O., Kaiserova, H., Adamcova, M., Hroch, M., Haskova, P., Ponka, P., and Gersl, V. (2008) Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. Br. J. Pharmacol. 155, 138-148.
37. Richardson, D. R., Sharpe, P. C., Lovejoy, D. B., Senaratne, D., Kalinowski, D. S., Islam, M., and Bernhardt, P. V. (2006) Dipyridyl thiosemicarbazone chelators with potent and selective anti-tumor activity form iron complexes with marked redox activity. J. Med. Chem. 49, 6510-6521.
38. Chaston, T., Lovejoy, D., Watts, R. N., and Richardson, D. R. (2003) Examination of the anti-proliferative activity of iron chelators: Multiple cellular targets and the different mechanism of action of Triapine compared to Desferoxamine and the potent PIH analogue 311. Clin. Cancer Res. 9, 402-414.
39. Wang, M., Wei, A. Q., Yuan, J., Trickett, A., Knoops, B., and Murrell, G. A. C. (2002) Expression and regulation of peroxiredoxin 5 in human osteoarthritis. FEBS Lett. 532, 359-362.
40. Yuan, J., Lovejoy, D. B., and Richardson, D. R. (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104, 1450-1458.
41. Myhre, O., Andersen, J. M., Aarnes, H., and Fonnum, F. (2003) Evaluation of the probes 2′,7′-dichlorofluorescin diacetate, luminol, and lucigenin as indicators of reactive species formation. Biochem. Pharmacol. 65, 1575-1582.
42. Richardson, D. R., and Baker, E. (1990) The uptake of iron and transferrin by the human malignant melanoma cell. Biochim. Biophys. Acta 1053, 1-12.
43. Richardson, D. R., and Baker, E. (1992) Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferriox-amine and ferric ammonium citrate. J. Biol. Chem. 267, 13972-13979.
44. Richardson, D. R., Tran, E. H., and Ponka, P. (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents. Blood 86, 4295-4306.
45. Baker, E., Richardson, D. R., Gross, S., and Ponka, P. (1992) Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-l-naphthylaldehyde using the hepatocyte in culture. Hepatology 15, 492-501.
46. Lentner, C. (1990) Geigy Scientific Tables, Vol. 5, Ciba-Geigy Limited, Basel.
47. Adamcova, M., Simunek, T., Kaiserova, H., Popelova, O., Sterba, M., Potacova, A., Vavrova, J., Malakova, J., and Gersl, V. (2007) In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology 237, 218-228.
48. Richardson, D. R., Ponka, P., and Baker, E. (1994) The effect of the iron(III) chelator, desferoxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res. 54, 685-689.
49. Darnell, G., and Richardson, D. R. (1999) The potential of analogues of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of the ligands on molecular targets involved in proliferation. Blood 94, 781-792.
50. Goldspink, D. F., Burniston, J. G., Ellison, G. M., Clark, W. A., and Tan, L. B. (2004) Catecholamine-induced apoptosis and necrosis in cardiac and skeletal myocytes of the rat in vivo: The same or separate death pathways? Exp. Physiol. 89, 407-416.
51. Clerk, A., Cole, S. M., Cullingford, T. E., Harrison, J. G., Jormakka, M., and Valks, D. M. (2003) Regulation of cardiac myocyte cell death. Pharmacol. Ther. 97, 223-261.
52. Kalinowski, D. S., Yu, Y., Sharpe, P. S., Islam, M., Liao, Y.-T., Lovejoy, D. B., Kumar, N., Bernhardt, P. V., and Richardson, D. R. (2007) Design, synthesis and characterization of novel iron chelators: Structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogs as potent anti-tumor agents. J. Med Chem 50, 3716-3729.
53. Diaz-Munoz, M., Alvarez-Perez, M. A., Yanez, L., Vidrio, S., Martinez, L., Rosas, G., Yanez, M., Ramirez, S., and de Sanchez, V. C. (2006) Correlation between oxidative stress and alteration of intracellular calcium handling in isoproterenol-induced myocardial infarction. Mol. Cell. Biochem. 289, 125-136.
54. Pinelli, A., Trivulzio, S., Tomasoni, L., Brenna, S., Bonacina, E., and Accinni, R. (2004) Isoproterenol-induced myocardial infarction in rabbits. Protection by propranolol or labetalol: A proposed non-invasive procedure. Eur. J. Pharm. Sci. 23, 277-285.
55. Lameris, T. W., de Zeeuw, S., Alberts, G., Boomsma, F., Duncker, D. J., Verdouw, P. D., Veld, A. J., and van Den Meiracker, A. H. (2000) Time course and mechanism of myocardial catecholamine release during transient ischemia in vivo. Circulation 101,2645-2650.
56. Schomig, A. (1990) Catecholamines in myocardial ischemia. Systemic and cardiac release. Circulation 82, II13 - 22.
57. Allen, D. R., Wallis, G. L., and McCay, P. B. (1994) Catechol adrenergic agents enhance hydroxyl radical generation in xanthine oxidase systems containing ferritin: Implications for ischemia/reper-fusion. Arch. Biochem. Biophys. 315, 235-243.
58. Rajan, K. S., Davis, J. M., and Colburn, R. W. (1971) Metal chelates in the storage and transport of neurotransmitters: Interactions of metal ions with biogenic amines. J. Neurochem. 18, 345-364.
59. Summers, M. R., Jacobs, A, Tudway, D., Perera, P., and Ricketts, C. (1979) Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br. J. Hamaetol. 42, 547-555.
60. Yeager, J. C., and Iams, S. G. (1981) The hemodynamics of isoproterenol-induced cardiac failure in the rat Circ. Shock 8, 151-163.
61. Bloom, S., and Davis, D. L. (1972) Calcium as mediator of isoproterenol-induced myocardial necrosis. Am. J. Pathol. 69, 459-470.
62. Behonick, G. S., Novak, M. J., Nealley, E. W., and Baskin, S. I. (2001) Toxicology update: the cardiotoxicity of the oxidative stress metabolites of catecholamines (aminochromes). J. Appl. Toxicol. 21 (Suppl. 1), S15-S22.
63. Neri, M., Cerretani, D., Fiaschi, A. I., Laghi, P. F., Lazzerini, P. E., Maffione, A. B., Micheli, L., Bruni, G., Nencini, C., Giorgi, G., D'Errico, S., Fiore, C., Pomara, C., Riezzo, I., Turillazzi, E., and Fineschi, V. (2007) Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats. J. Cell. Mol. Med 11, 156-170.
64. Singal, P. K., Kapur, N., Dhillon, K. S., Beamish, R. E., and Dhalla, N. S. (1982) Role of free radicals in catecholamine-induced cardiomyopathy. Can. J. Physiol. Pharmacol. 60, 1390-1397.
65. Singal, P. K., Beamish, R. E., and Dhalla, N. S. (1983) Potential oxidative pathways of catecholamines in the foimation of lipid peroxides and genesis of heart disease. Adv. Exp. Med. Biol. 161, 391-401.
66. Strubelt, O., and Siegers, C. P. (1975) Role of cardiovascular and ionic changes in pathogenesis and prevention of isoprenaline-induced cardiac necrosis. Recent Adv. Stud Card. Struct. Metab. 6, 135-142.
67. Napier, I., Ponka, P., and Richardson, D. R. (2005) Iron trafficking in the mitochondrion: Novel pathways revealed by disease. Blood 105, 1867-1874.
68. Berenshtein, E., Vaisman, B., Goldberg-Langerman, C., Kitrossky, N., Konijn, A. M., and Chevion, M. (2002) Roles of ferritin and iron in ischemic preconditioning of the heart. Mol. Cell. Biochem. 234 - 235, 283-292.
69. Graf, E., Mahoney, J. R., Bryant, R. G., and Eaton, J. W. (1984) Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site. J. Biol. Chem. 259, 3620-3624.
70. Pippard, M. J., Callender, S. T., and Finch, C. A. (1982) Ferrioxamine excretion in iron-loaded man. Blood 60, 288-294.